teria decision analysis. CONCLUSIONS: These and other methods may be used by CONs in assessing the intensity of efficiency and, in turn, by decision makers. Thus, it is expected to contribute to the development and application of these decision-support tools and to improve the criteria of Ministry of Health for deciding which technologies to fund.

PHP130 THE RELEVANCE OF HEALTH TECHNOLOGY ASSESSMENT OF DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TESTS IN ONCOLOGY: PROSPECTS FOR IMPLEMENTATION IN RUSSIA

Yegudkin B.1, Borokovkov IV1
1M. S. Sorbonne First Moscow State Medical University, Moscow, Russia

OBJECTIVES: An application of predictive and pharmacogenetic tests in appoint- ment of targeted anti-cancer therapy and predict response to treatment. Considering significant practical necessity of molecular-genetic methods for health care and high investment into these projects, we evaluate these technologies. METHODS: A systematic review of articles has been conducted using databases PubMed, The Cochrane Library, and published reports and market reviews. RESULTS: In the period from 2007 to 2012 it is estimated the world market in vitro diagnostic (IVD) procedure is increasing due to the development of molecular diagnostic tests and rapid test kits. Experts point out that a key factor in the growth segment of molecular diagnostics in recent years has been precisely the emergence of new oncology tests to prescribe targeted therapy. At the moment, in IVD diagnostics segment in Russia market is forecasted growth rate for 2014 at 10-20%. Price of tests for oncology biomarkers depends on the technology: - for most routine immunological and biochemical tests is between 10 and 15 USD; - for molecular genetic tests costs varies from 200 to 1000 USD. In addition, KRAS- and EGFR-test, in this review discussed the practical value of testing EML4-ALK mutation for crizotinib in non-small lung cancer; BRAF V600E-testing for vemurafenib in melanoma; HER2/neu-testing for trastuzumab in breast cancer. Thus, the Russian segment of the cancer diagnostics market is the fast-growing market. However, the analysis of the literature showed that until that time in the Russian Federation was not conducted clinical and economic evaluation of these medical technologies. CONCLUSIONS: The analysis revealed that evaluation of diagnostic test systems in oncology from the point of view of health economics of the Russian Federation is a topical field for research and requires a rigorous analysis.

PHP131 QUANTIFYING THE VALUE OF TRANSITIONAL CARE PHARMACY SERVICES

Baker B.1, University of Kentucky, Lexington, KY

Transitional care management programs have been shown to improve medication adherence, elevate patient comprehension of their disease state, increase patient satisfaction, and elevate patient comprehension of their disease state. A drug network model, while Federation, can help identify features such as accessibility to medicines and affordability of medicines and adherence to right treatment. Yet, we identify key variables in each of these pillars and compare and rank countries with more than 60% of the world's population on each of these variables, at an aggregate level on each pillar, and overall. We draw upon IMA data as well as international and country level sources to obtain the data needed for the measures. We then look at the features that countries and policies around the world use to improve patient satisfaction, quality of care, and, ultimately, overall health status. This paper will model how medical, social, economic, and political factors influence the access to medicines and explore configurations and policies that lead to better performance on the index.

PHP132 PHARMACEUTICAL PAYMENT REFORM OF TAIWAN, NHI

Shih LC.1, Shu-Cheng L2
1Ministry of Health and Welfare, Taiwan, ROC; 2Taipei City, Taiwan (ROC), Taiwan

The National Health Insurance (NHI) Program in Taiwan is a mandatory govern- ment-run social insurance system cover 99% of the population. Since its inception in 1995, NHI has been facing the challenges of rapid increase on health care costs, particularly in 1998, nominal growth rate of NHI costs reached 11.4% per year. So many strategies have been introduced in controlling costs and in improving qual- ity of care, and the Second-Generation NHI was implemented in January 1, 2013. Among them the pharmaceutical benefits and expenditures strategies were the most important. First, it focus to four categories, pharmaceuticals, hospitals, medical services and biotechnology. In 2012, nearly 25% of total health insurance expenditure, and drug cost per capita was 204 USD. Over 18,000 drugs were listed in the Drug Price List, and average new drugs listed per year was 144 days. The average growth rate on drug fees was 4.8% for recent 10 years. Many strategies had been introduced to control drug costs, such that: (1) Drug Price List was revised continuously based on setting reference prices for the drugs with the same ingredients. The price was adjusted 9 times from 2000 to 2011. (2) Drug Expenditure. The practice in NHI was also limited in price setting. (3) Limiting the drug fees rising, and make drug policy predictable to the pharmaceutical industrial in Taiwan. (3) other reform such as focused on efficient pharmaceutical benefits and payment systems, equity in pharmaceutical transactions, public participation and information transparency. However, these biggest reform are now high hopes

that the launch of the NHI system. To improve the system even further, future chal- lenge will be our motive to reform and also lead us to a new stage in health care.

PHP133 CONCEPTUAL FRAMEWORK CHARACTERIZING NEUROCOGNITIVE BURDEN ASSOCIATED WITH PRIMARY central NORTHERN PROGRESSION

Bartley E.1, Theodore-Oklota C., Campbell A.
1Genentech, South San Francisco, CA, USA

Glioblastoma (GBM) is an aggressive, high-grade glioma characterized by rapid growth and microvascular proliferation. Tumors are typically localized to the central nervous and rarely distantly metastasize. Worsening of neurocognitive symptoms is observed with GBM progression, and can significantly impact patient function and quality of life. Current treatments are non-curative and have not demonstrated an increase in overall survival. Progression-free survival (PFS) is a common pri- mary endpoint in clinical trials of GBM therapies; however, it is important in this patient population to quantify how time without disease progression benefits patients. Recent decisions by health authorities and payers suggest an increasing trend towards the need for evidence of patient-centered endpoints, particularly for reimbursement decision-making. Assessment of neurocognitive deterioration due to GBM progression during the clinical trial period is challenging given the need to sensitively assess a range of symptoms that may manifest due to lesions in differ- ent regions of the brain. A disease model, or conceptual framework, is needed to ground decision-making around choice of instruments, endpoints, and schedules of symptom assessments, thus ensuring measurement of the most patient and bio- logically relevant symptoms. The framework presented here outlines the biological processes that contribute to non-focal symptoms of GBM, such as headache, as well as the behavioral and cognitive symptoms that can be assessed in clinical trials, changes in verbal and expression. Considerations and challenges in assessing neurocognitive symptoms in early GBM patients utilizing existing tools and methodologies are reviewed and identified.

PHP134 EVIDENCE BASED APPROACH TO EVALUATE AND IMPROVE ACCESS TO MEDICINES IN EMERGING MARKETS

Shanker B.1, Hickson S.2, Sabat A.1,2
1IMS Consulting Group, Cambridge, UK; 2IMS Consulting Group, Mumbai, India

Developed countries have largely achieved universal health care coverage, while many developing countries are implementing steps to increase health care cover- age. While the objective is the same, the health care systems and policies across countries differ across countries leading to different levels of access to medicines. To understand how systems and policies can lead to better access, we need a measure to evaluate how well countries do in terms of providing access to medi- cine for their populations. In this paper, we develop a Country Access to Medicines Index that compares and ranks countries on access to medicine outcomes. This index measures how accessibility to medicines, pharmaceuticals, and facilities, awareness of disease diagnosis and treatment, availability of medicines, affordability of medicines and adherence to right treatment. We identify key variables in each of these pillars and compare and rank countries with more than 60% of the world's population on each of these variables, at an aggregate level on each pillar, and overall. We draw upon IMS data as well as international and country level sources to obtain the data needed for the measures. We then look at the features that countries and policies around the world use to improve patient satisfaction, quality of care, and, ultimately, overall health status. This paper will model how medical, social, economic, and political factors influence the access to medicines and explore configurations and policies that lead to better performance on the index. We find that five broad factors can help explain access to medicines performance. First is the level of financing of health care, espe- cially reimbursement coverage. Second is a structured and transparent pricing and reimbursement decision-making. Assessment of neurocognitive deterioration due to GBM progression during the clinical trial period is challenging given the need to sensitively assess a range of symptoms that may manifest due to lesions in differ- ent regions of the brain. A disease model, or conceptual framework, is needed to ground decision-making around choice of instruments, endpoints, and schedules of symptom assessments, thus ensuring measurement of the most patient and bio- logically relevant symptoms. The framework presented here outlines the biological processes that contribute to non-focal symptoms of GBM, such as headache, as well as the behavioral and cognitive symptoms that can be assessed in clinical trials, changes in verbal and expression. Considerations and challenges in assessing neurocognitive symptoms in early GBM patients utilizing existing tools and methodologies are reviewed and identified.

PHP135 THE INFLUENTIAL PATIENT: ROLE OF PATIENT OPINION LEADERS ON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, HEALTH POLICY, AND COMMERICALIZATION

Ko L.1, Godley P.1
1Scott & White Health Plan/Univ of Texas Novartis Pharmaceuticals Corp., Temple, TX, USA

The increasing adoption of Internet and social media have facilitated the emergence of patient opinion leaders (POLs). These influential individuals are living with a chronic disease and are writing about their experiences on Internet blogs and social media websites. Popular and highly-trusted patients are labeled as POLs because their work influences the decision-making of other patients. Top POLs have tens of thousands of followers who subscribe to their websites, blogs, and online social media accounts. POLs usually focus on one therapeutic area and provide disease-related information, treatment options, and emotional support to other patients. Additionally, some POLs are health activists who help shape health policy and provide input into clinical trial design including endpoint development. As health care increases its focus to center around the individual patient, pharmaceutical companies and government agencies will seek out POLs for their personal perspectives. This paper will discuss whether the use of POLs in clinical trials as subject matter experts, and the potential for POLs to influence patient access to health care. Finally, a model that ensures the proper implementation of health policy initiatives.